KDM5B / JARID1B is a histone demethylase involved in development and differentiation processes, in DNA damage repair, in gene expression regulation, in cancerogenesis and drug resistance. Although KDM5B is up regulated in many types of cancer, it may have a different function in luminal and basal breast cancers. Until now remains unclear what contextual determinants dictate whether KDM5B protein function as oncogene or tumor suppressor. Recently it has been proposed that the relative abundance of different KDM5B isoforms may contribute to tumor progression in melanoma, but the significance of the alternative transcripts of PLU-1 remains unclear. In this regard, a predicted protein isoform X1, never validated until now, is of particular interest. In fact, this expected isoform, lacking an N-terminal portion, may act as a negative dominant, maintaining the ability to bind chromatin and coregulators but losing its catalytic demethylase function. At the same time, it is possible that this isoform may also become a gain of function, since it includes an alternative exon that is not present in the canonical protein isoform, by giving the protein the ability to bind new interactors. Therefore, the understanding of the biological contribution of this and other protein predicted isoforms for tumor progression and chemoresistance in breast cancer and melanoma may be of crucial importance.
KDM5B/JARID1B is a histone demethylase involved in development and differentiation processes, in DNA damage repair, in cancer and, more generally, in the regulation of gene expression16,17,39.
Of the all KDM5 proteins upregulated in cancers, the relationship between KDM5B and tumorigenesis is maybe the most studied thus far. Nonetheless, until now remains unclear what contextual determinants dictate whether KDM5B protein function as oncogene or tumor suppressor. We think, thus, that the characterization of KDM5B isoforms could be of fundamental importance to understand their role in tumor progression, shedding light on the many often contradictory observations according to which KDM5B acts in opposite way depending on tumor context. In this regard, it is likely that the relative amount of different protein isoforms in various tumor cell lines may have an association with tumor malignancy. Moreover, understanding the role of KDM5B isoforms in tumor progression could prove to be essential for the identification of new combined therapeutic technologies in tumors in which KDM5B targeting plays a key role, such as in breast cancer.
References
1. Jambhekar A, Dhall A, Shi Y. Roles and regulation of histone methylation in animal development. Nat Rev Mol Cell Biol. 2019;20(10):625-641.
2. Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006;7(9):715-727.
3. Dimitrova E, Turberfield AH, Klose RJ. Histone demethylases in chromatin biology and beyond. EMBO Rep. 2015;16(12):1620-1639.
4. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381-395.
5. Barski A, Cuddapah S, Cui K, et al. High-Resolution Profiling of Histone Methylations in the Human Genome. Cell. 2007;129(4):823-837.
6. Xie L, Pelz C, Wang W, et al. KDM5B regulates embryonic stem cell self-renewal and represses cryptic intragenic transcription. EMBO J. 2011;30(8):1473-1484.
7. Li X, Liu L, Yang S, et al. Histone demethylase KDM5B is a key regulator of genome stability. Proc Natl Acad Sci U S A. 2014;111(19):7096-7101.
8. Di Nisio, Elena; Lupo, Giuseppe; Licursi, Valerio; Negri, Rodolfo. 2021 - The role of histone lysine methylation in the response of mammalian cells to Ionizing radiation In: FRONTIERS IN GENETICS, Frontiers Research Foundation, 2021, Vol. 12 - ISSN: 1664-8021
9. Gong F, Clouaire T, Aguirrebengoa M, Legube G, Miller KM. Histone demethylase KDM5A regulates the ZMY ND8-NuRD chromatin remodeler to promote DNA repair. J Cell Biol. 2017;216(7):1959-1974.
10. Mocavini I, Pippa S, Licursi V, et al. JARID1B expression and its function in DNA damage repair are tightly regulated by miRNAs in breast cancer. Cancer Sci. 2019;110(4):1232-1243.
11. Kuzbicki L, Lange D, Stanek-Widera A, Chwirot BW. Prognostic significance of RBP2-H1 variant of JARID1B in melanoma. BMC Cancer. 2017;17:854.
12. Vogt T, Kroiss M, McClelland M, Gruss C, Becker B, Bosserhoff AK, Rumpler G, Bogenrieder T, Landthaler M, Stolz W. Deficiency of a novel retinoblastoma binding protein-2 homolog is a consistent feature of sporadic human melanoma skin cancer. Lab Invest 1999;79:1615¿27.
13. Barrett A, Madsen B, Copier J, et al. PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: A new cancer/testis antigen? Int J Cancer. 2002;101(6):581-588.
14. Anvar SY, Allard G, Tseng E, et al. Full-length mRNA sequencing uncovers a widespread coupling between transcription initiation and mRNA processing. Genome Biol. 2018;19(1):1-18.